Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00114218 · BASELINE

Baseline characteristics

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer · Source last updated 2019-01-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      24
    units
    Participants
groups
  1. description
    Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Gemcitabine Hydrochloride: Given IV Docetaxel: Given IV
    id
    BG000
    title
    Treatment (Gemcitabine Hydrochloride, Docetaxel)
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      <50 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          5
      title
      50-59 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          12
      title
      60-69 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      70-79 years
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      >79 years
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Age, Customized
    unit Of Measure
    Participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          24
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Eligible and treated patients
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      24
    units
    Participants
groups
  1. description
    Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Gemcitabine Hydrochloride: Given IV Docetaxel: Given IV
    id
    BG000
    title
    Treatment (Gemcitabine Hydrochloride, Docetaxel)
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      <50 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          5
      title
      50-59 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          12
      title
      60-69 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      70-79 years
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      >79 years
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Age, Customized
    unit Of Measure
    Participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          24
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Eligible and treated patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice